Exercise option 2 for FDA approved radioactive drugs from cardinal health for the NIH-CC nuclear medicine department (pots 25-000247). $500,000 FY2025 funding under requirements contract & master…
Ended Awarded Last action
- Contract number
- 75N90025F00001
- Awardee
-
Cardinal Health 414, LLC UEI CWN9UGL3NCL9 Part of Cardinal Health, Inc.
- Awarding agency
-
NIH Clinical Center
National Institutes of Health, Department of Health and Human Services
- Obligated
- $800,000
Award facts
- Contract value 100% obligated
- $800,000.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- Set-aside
- No set-aside
- Competition
- Not Competed Only One Source
- Pricing
- Firm Fixed Price
- Place of performance
- Dublin, OH 43017, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | $300,000 | |
| Original award | $500,000 |
About this award
The National Institutes of Health Clinical Center awarded a $500,000 delivery order in Fiscal Year 2025 to Cardinal Health 414, LLC for FDA-approved radioactive drugs to support the NIH-CC Nuclear Medicine Department. This delivery order exercises Option 2 under master contract 75N90023D00003, a requirements contract with a ceiling value of $800,000 and an ultimate completion date of September 30, 2025. The contract carries no set-aside designation and is structured as a firm fixed-price delivery order. Cardinal Health 414, LLC, a subsidiary of Cardinal Health, Inc. headquartered in Dublin, Ohio, is the prime contractor responsible for manufacturing, testing, and distributing radiopharmaceuticals and medical isotopes from its primary facility in Dublin, Ohio.
Cardinal Health 414 specializes in supplying time-sensitive nuclear medicine and diagnostic imaging products essential for federal healthcare operations, with particular expertise in radiopharmaceuticals including technetium-99m, iodine-123, iodine-131, indium-111, thallium-201, and fluorine-18 fluorodeoxyglucose (FDG). The company maintains extensive federal contracting relationships across multiple agencies and holds numerous Indefinite Delivery Contracts with Veterans Integrated Service Networks, the Defense Health Agency, and the National Institutes of Health, demonstrating its established role as a critical supplier of specialized radiopharmaceutical products to the federal healthcare system.
Description
Exercise option 2 for FDA approved radioactive drugs from cardinal health for the NIH-CC nuclear medicine department (pots 25-000247). $500,000 FY2025 funding under requirements contract & master contract# 75N90023D00003. Additional funds will be
Quick answers
Who was awarded contract 75N90025F00001?
75N90025F00001 was awarded to Cardinal Health 414, LLC by NIH Clinical Center (National Institutes of Health) on October 1, 2022.
How much is contract 75N90025F00001 worth?
The government has obligated $800,000 on 75N90025F00001.
Is contract 75N90025F00001 an order under another contract?
Yes. 75N90025F00001 is a delivery order under 75N90023D00003, an indefinite delivery contract.
Was contract 75N90025F00001 competed?
The extent of competition for 75N90025F00001 was not competed.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award